British Healthcare: Announcement on the completion of partial restricted stock repurchases and cancellation of the restricted stock incentive plan
British Healthcare: Announcement on Cancellation and Cancellation of Certain Restricted Stock Repurchases and Adjustments to Inke\'s Debt-for-Share Convertible Prices
British Healthcare: Announcement on the progress of providing guarantees to subsidiaries
British Healthcare: Announcement on progress in the repurchase of the company\'s shares
British Healthcare: Announcement on the conversion of convertible corporate bonds to shares for the third quarter of 2024
British Healthcare: Announcement on the progress of providing guarantees to subsidiaries
British Healthcare: Announcement on the cancellation of the pledge of some of the controlling shareholder\'s shares
British Healthcare: Announcement on the initial repurchase of the company\'s shares
British Healthcare: Buyback Report
British Healthcare: Announcement on the shareholding status of the company\'s top ten shareholders and the top ten shareholders with unlimited sales conditions
British Healthcare: Announcement of Resolutions of the 25th Meeting of the 3rd Board of Directors
British Healthcare: Announcement on the company\'s share repurchase plan
British Healthcare: Announcement of Resolutions of the 23rd Meeting of the 3rd Board of Supervisors
British Healthcare: Legal Opinion of Shanghai Zechang Law Firm on the 2024 Third Extraordinary General Meeting of Shareholders of Inke Medical Technology Co., Ltd.
British Healthcare: Announcement of Resolutions of the 2024 Third Extraordinary General Meeting of Shareholders
British Healthcare: 300677 Yingke Healthcare Investor Relations Management Information 20240829
British Healthcare: Announcement on the cancellation of the pledge of some of the controlling shareholder\'s shares
British Healthcare: Announcement on participating investment funds from professional investment institutions
British Healthcare: Announcement of Board Resolutions
British Healthcare: Summary table of non-operating capital expenditure and other related capital transactions for the 2024 semi-year
No Data
No Data